LENNARD HERBST
Prescription History 1437255643
Obstetrics & Gynecology in Westminster, MD


Quality Rating: 52.15 out of 100 score

NPI Status: Active since September 15, 2006

Contact Information

844 WASHINGTON RD STE 302
WESTMINSTER, MD
ZIP 21157
Phone: (410) 876-2003
Fax: (410) 848-3009

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LENNARD HERBST, an active Obstetrics & Gynecology specialist practicing in Westminster, MD. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 76 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 30 claims alone.

Medication Index

No matching medications currently found on file.

Clotrimazole-Betamethasone

Generic Formulation: Clotrimazole/Betamethasone DipSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 351
MD State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills21.0
Peer Average Days Supply489
Conservative Utilization

This provider writes prescriptions for this formulation 26.3% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $627.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.83

State Avg Cost Per Claim

$33.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. This product contains 2 medications. Clotrimazole is an azole antifungal that works by preventing the growth of fungus. Betamethasone is a strong corticosteroid that works by reducing the swelling, redness, and itching that occurs in the skin infection. This medication is not recommended for children younger than 17 years or for diaper rash.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 30
30-Day Fills 81.7
Days Supply 2,452
MD State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills80.1
Peer Average Days Supply2,388
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $688.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.95

State Avg Cost Per Claim

$101.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 48.0
Days Supply 1,440
MD State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills44.4
Peer Average Days Supply1,325
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,438.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$89.89

State Avg Cost Per Claim

$113.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Solifenacin Succinate

Generic Formulation: Solifenacin SuccinateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 32.0
Days Supply 960
MD State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills52.6
Peer Average Days Supply1,568
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $782.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.90

State Avg Cost Per Claim

$102.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Therapeutic Applications

Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LENNARD HERBST provides transparency into local medical care patterns within Westminster, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.